1. Market Research
  2. > Pharmaceutical Market Trends
  3. > IMS Pharmaceutical Pricing & Reimbursement Concise Guide: Hungary

The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS pricing and reimbursement specialists to provide industry players and decision makers with a thorough understanding of the rules and regulations governing P&R in international markets. This report covers key developments in P&R, market access, cost containment, trade margins and healthcare issues.

Table Of Contents

IMS Pharmaceutical Pricing and Reimbursement Concise Guide: Hungary
HUNGARY 1
HEALTHCARE SYSTEM1
Facts and Figures1
Market Indicators2
Provision and Funding4
Healthcare Provision4
Healthcare Funding5
Healthcare Reform6
PRICING9
Prescription Drugs9
Application9
Assessment9
Listing Agreements 10
Timelines11
Generic Drugs11
Biosimilars13
Hospital Drugs13
Procurement13
Hospital Debts 14
OTC Drugs 14
REIMBURSEMENT14
Admission to Reimbursement14
Basic Criteria15
Standard and Simplified Procedures15
Application16
Assessment17 Appeals18
Timelines18
Beneficiary Status Reimbursement19
Named Patient Programme20
Compassionate Use21
Reimbursement Categories21
Normative Reimbursement22
Indication-bound Reimbursement22
Other Categories24
Reimbursement Prices26
Active Ingredient Reference Pricing26
Therapeutic Reference Pricing 27
Biologic Drugs Reference Pricing 27
Reference Price System Updates27
Hospital Reimbursement30
Formularies30
Funding31
Changes in Reimbursement Status32
Delisting 32
Reimbursement Categories33
Changes in Reimbursement Prices33
Price Changes33
Price Reviews 33
Reference Pricing System34
PHARMACOECONOMICS 35
Pharmacoeconomic Requirements35
Overview35
Procedure35
Decision36
Guidelines36
PRICE BUILD UP37
Wholesalers37
Margins37
Rebate38
Background38
Retail Pharmacies38
Margins38
Additional Fees39
Background39
Dispensing Doctors41
Sales Tax42
COST CONTAINMENT42
Industry Paybacks42
Budget Excess Repayments42
Clawback43
Additional Clawback44
Pharmaceutical Sales Representative Fee44
Promotional Costs45
Advertising 45
Sales Representatives45
Payments to Healthcare Professionals45
Codes of Conduct46
Patient Co-payments46
Pharmaceuticals 46
Healthcare47
Prescribing Controls48
Prescription Feedback48
Traffic Light System48
Prescribing Guidelines49
Prescribing Restrictions49

Decision 18
Indication-bound Reimbursement49
INN Prescribing50
Electronic Prescribing50
Generics50
Generic Dispensing Incentives 50
Generic Substitution51
INN Prescribing 51
Other Initiatives 51
Rx-to-OTC Switches51
Parallel Trade52
FUTURE DEVELOPMENTS52
Outlook52
Hospital Sector Debts 52
E-Health Initiatives53
NAMES and ADDRESSES53

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.